CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $6.3M, lower than 95% of all stocks globally
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
As of FY2024 (year ended December 31, 2024). Newer annual figures aren't yet on file.
Financials view
Market Capitalization
20.64MILS6.30M · vs all stocks (USD)
Revenue (TTM)
0.00ILA150.03K · vs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
0.4610xvs all stocks
52-Week Change
-58.00%vs all stocks
Market Capitalization
20.64MILS6.30M · vs all stocks (USD)
Enterprise Value
0.00ILSvs all stocks (USD)
Enterprise to EBITDA
-17.02xvs Biotechnology peers
Gross Margin
-14.88%vs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-21.01%vs Biotechnology peers
Revenue (TTM)
0.00ILA150.03K · vs all stocks (USD)
Revenue per Share (TTM)
0.00ILAUpdated Aug 12, 2026Quarterly Revenue Growth
78.40%vs Biotechnology peers
Gross Profit (TTM)
0.00ILA997.95 · vs all stocks (USD)
Net Income (TTM)
-6.97MILA-341.63K · vs all stocks (USD)
Operating Cash Flow (TTM)
-1.02MILA-155.35K · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-6.97MILA-341.63K · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00ILSUpdated Aug 12, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
451.00KUSDFY2024 · Dec 31, 2024Cost of Goods Sold
448.00KUSDFY2024 · Dec 31, 2024Gross Profit
3.00KUSDFY2024 · Dec 31, 2024Operating Income
-2.17MUSDvs all stocks (USD)
Pre-tax Income
-1.16MUSDFY2024 · Dec 31, 2024Income Tax Expense
-130.00KUSDFY2024 · Dec 31, 2024Net Income
-1.03MUSDFY2024 · Dec 31, 2024EBIT
-1.13MUSDFY2024 · Dec 31, 2024EBITDA (Income Statement)
-2.00MUSDFY2024 · Dec 31, 2024Research & Development
98.00KUSDFY2024 · Dec 31, 2024Selling, General & Administrative
2.05MUSDFY2024 · Dec 31, 2024Non-operating Interest Income
34.00KUSDFY2024 · Dec 31, 2024Non-operating Interest Expense
28.00KUSDFY2024 · Dec 31, 2024EPS (Basic)
-0.0020USDFY2024 · Dec 31, 2024EPS (Diluted)
-0.0030USDFY2024 · Dec 31, 2024Basic Shares Outstanding
673.04MSharesFY2024 · Dec 31, 2024Diluted Shares Outstanding
673.04MSharesFY2024 · Dec 31, 2024Net Income from Continuing Operations
-1.03MUSDFY2024 · Dec 31, 2024Operating Cash Flow
-467.00KUSDFY2024 · Dec 31, 2024Free Cash Flow
-521.00KUSDFY2024 · Dec 31, 2024Cash & Cash Equivalents (End of Period)
371.00KUSDFY2024 · Dec 31, 2024Starting Profit (CF Statement)
-1.03MUSDFY2024 · Dec 31, 2024Depreciation & Amortization
199.00KUSDFY2024 · Dec 31, 2024Deferred Taxes (CF)
-130.00KUSDFY2024 · Dec 31, 2024Stock-based Compensation
264.00KUSDFY2024 · Dec 31, 2024Other Non-cash Items
-20.00KUSDFY2024 · Dec 31, 2024Change in Accounts Receivable (CF)
39.00KUSDFY2024 · Dec 31, 2024Change in Accounts Payable (CF)
208.00KUSDFY2024 · Dec 31, 2024Capital Expenditures
-54.00KUSDFY2024 · Dec 31, 2024Net Acquisitions
-410.00KUSDFY2024 · Dec 31, 2024Purchase of Investments
-14.00KUSDFY2024 · Dec 31, 2024Other Investing Activity
-400.00KUSDFY2024 · Dec 31, 2024Net Investing Cash Flow
-878.00KUSDFY2024 · Dec 31, 2024Long-term Debt Payments
-13.00KUSDFY2024 · Dec 31, 2024Net Short-term Debt Issuance
-13.00KUSDFY2024 · Dec 31, 2024Net Financing Cash Flow
1.43MUSDFY2024 · Dec 31, 2024Shares Outstanding
946.24MSharesUpdated Aug 12, 2026Float Shares
600.77MSharesUpdated Aug 12, 2026% Held by Insiders
44.05%vs all stocks
% Held by Institutions
0.00%vs all stocks
Total Cash (MRQ)
76.00KILA123.41K · vs all stocks (USD)
Total Cash per Share (MRQ)
0.00ILAUpdated Aug 12, 2026Total Debt (MRQ)
0.00ILAUpdated Aug 12, 2026Current Ratio (MRQ)
0.3950xvs Biotechnology peers
Book Value per Share (MRQ)
0.00ILAUpdated Aug 12, 2026Total Assets
8.55MUSDvs all stocks (USD)
Total Current Assets
1.34MUSDFY2024 · Dec 31, 2024Total Liabilities
3.12MUSDFY2024 · Dec 31, 2024Total Non-current Assets
7.21MUSDFY2024 · Dec 31, 2024Total Non-current Liabilities
908.00KUSDFY2024 · Dec 31, 2024Total Current Liabilities
2.21MUSDFY2024 · Dec 31, 2024Cash
371.00KUSDFY2024 · Dec 31, 2024Cash Equivalents
0.00USDFY2024 · Dec 31, 2024Cash & Cash Equivalents
371.00KUSDFY2024 · Dec 31, 2024Other Short-term Investments
772.00KUSDFY2024 · Dec 31, 2024Accounts Receivable
99.00KUSDFY2024 · Dec 31, 2024Accounts Payable
196.00KUSDFY2024 · Dec 31, 2024Short-term Debt
138.00KUSDFY2024 · Dec 31, 2024Deferred Revenue
18.00KUSDFY2024 · Dec 31, 2024Other Current Liabilities
1.28MUSDFY2024 · Dec 31, 2024Common Stock (Book)
23.14MUSDFY2024 · Dec 31, 2024Retained Earnings
-159.01MUSDFY2024 · Dec 31, 2024Total Shareholders' Equity
5.43MUSDvs all stocks (USD)
52-Week Low
1.60ILAUpdated Aug 12, 202652-Week High
11.80ILAUpdated Aug 12, 202652-Week Change
-58.00%vs all stocks
Beta
0.4610xvs all stocks
50-Day MA
1.91ILAUpdated Aug 12, 2026200-Day MA
0.5880ILAUpdated Aug 12, 2026Avg 10-Day Volume
984.26KSharesUpdated Aug 12, 2026Avg 30-Day Volume
2.88MSharesUpdated Aug 12, 2026Diluted EPS (TTM)
-0.0080ILAUpdated Aug 12, 2026Other Income / Expense
1.07MUSDFY2024 · Dec 31, 20243 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Diagnostic
Goodwill-Heavy Equity
Equity looks heavy for the industry, but much of it is goodwill from past acquisitions.
Reads
Intangible Concentration
Much of what it owns is goodwill from past deals, large next to its equity.
Reads
Is this company growing?
Diagnostic
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $6.3M, lower than 95% of all stocks globallySignificant
Market cap (USD): 6,295,357.047Global P5: 269,387,740.27
Revenue is $150,025, lower than 95% of all stocks globallySignificant
Revenue (USD): 150,025.15Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Sulzer Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Purple Biotech Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Thalia Therapeutics Plc
Tier 1ProductionApproval-Gated PipelineRule
TheracryF PLC
Tier 1ProductionApproval-Gated PipelineRule
Nuformix Plc
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Sailong Pharmaceutical Group Inc.
Tier 1ProductionApproval-Gated PipelineRule
Crism Therapeutics Corporation
Tier 1ProductionApproval-Gated PipelineRuleRisk
Cizzle Biotechnology Holdings Plc
Tier 1ProductionApproval-Gated PipelineRule
Futura Medical plc
Tier 1ProductionApproval-Gated PipelineRule
Genflow Biosciences Plc
Tier 1ProductionApproval-Gated PipelineRuleRisk
Companies that share active interpretations — structural patterns currently present in both stocks.
Mesoblast Limited
3 interpretationsGoodwill-Heavy EquityIntangible ConcentrationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Olaplex Holdings, Inc.
2 interpretationsGoodwill-Heavy EquityIntangible Concentration
Tribal Group plc
2 interpretationsGoodwill-Heavy EquityIntangible Concentration